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The incidence of prostate cancer is much lower in Asian than in Western populations. Lifestyle and di-
etary habits may play a major role in the etiology of this cancer. Given the possibility that risk factors for
prostate cancer differ by disease aggressiveness, and the fact that 5-year relative survival rate of localized
prostate cancer is 100%, identifying preventive factors against advanced prostate cancer is an important
goal.
Using data from the Japan Public Health Center-based Prospective Study, the author elucidates various
lifestyle risk factors for prostate cancer among Japanese men. The results show that abstinence from
alcohol and tobacco might be important factors in the prevention of advanced prostate cancer. Moreover,
the isoﬂavones and green tea intake in the typical Japanese diet may decrease the risk of localized and
advanced prostate cancers, respectively.
© 2016 The Author. Publishing services by Elsevier B.V. on behalf of The Japan Epidemiological
Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Although the incidence of prostate cancer in Japan is rapidly
increasing, it is still much lower than in Western populations.1
However, Japanese migrants to the United States and Brazil have
increased incidence,2,3 and the incidence of latent or clinically
insigniﬁcant prostate cancer between Asian countries and the
United States is similar in autopsy studies.4,5 Therefore, it has been
suggested that environmental factors may play an important role in
the progression of prostate cancer.
In addition, although prostate cancer is clinically diagnosed as
local (i.e., conﬁned to the prostate) or advanced (i.e., distantly
spread), studies of the association of various suspected risk factors
with aggressive prostate cancer have been conﬂicting.6 Risk factors
for localized prostate cancer might differ from those for advanced
prostate cancer. Moreover, the 5-year relative survival rate of pa-
tients with localized prostate cancer is 100%,7 so it is important to
focus preventive efforts on advanced prostate cancer.
The Japan Public Health Center-based Prospective (JPHC) Study
is a large-scale population-based prospective study that has been
conducted since 1990 in 11 public health center-based areas across
Japan. The subjects were 140,420 residents aged 40e69 years.Elsevier B.V. on behalf of The Japan
d/4.0/).Questionnaires, blood samples, and health screening data were
collected. We have followed this cohort for over 20 years, and a
sufﬁcient number of incident cancers has accumulated, although
the number of prostate cancer cases is still lower than would be
expected in Western countries.
Here, to elucidate the inﬂuence of risk factors for prostate cancer
d namely tobacco smoking, alcohol drinking, body mass index
(BMI), and diet d on prostate cancer according to stage, we con-
ducted cohort analyses using data from the JPHC Study.2. JPHC study
The JPHC Prospective Study started in 1990 for Cohort I and in
1993 for Cohort II. The study design has been described in detail
elsewhere.8 Cohort I consisted of ﬁve Public Health Center (PHC)
areas, involving the following PHC centers (Prefecture): Ninohe
(Iwate), Yokote (Akita), Saku (Nagano), Chubu (Okinawa), and
Katsushika (Tokyo); while Cohort II consisted of six PHC areas, with
the following PHC centers (Prefecture): Mito (Ibaraki), Nagaoka
(Niigata), Chuo-higashi (Kochi), Kamigoto (Nagasaki), Miyako
(Okinawa), and Suita (Osaka). The study population was deﬁned as
all residents aged 40e59 years in Cohort I and 40e69 years in
Cohort II at the start of the respective baseline survey. This study
was approved by the institutional review board of the National
Cancer Center of Japan. For the analysis in this review, theEpidemiological Association. This is an open access article under the CC BY-NC-ND
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not available.
The questionnaire was distributed primarily by hand from 1990
to 1994 (baseline survey). Approximately 113,000 people returned
the questionnaire, and 48,000 provided blood samples or health
checkup data, with most providing both. To update information on
lifestyle and health conditions, a 5-year follow-up questionnaire
survey was conducted from 1995 to 1999. In the 5-year survey, we
asked subjects to respond to a comprehensive food frequency
questionnaire (147 food item and beverages), so the 5-year ques-
tionnaire was used as the starting point for the association between
diet and prostate cancer. The response rate was around 80%. Sub-
jects with a history of prostate cancer were excluded from these
analyses.
Information on the cause of death for deceased subjects was
obtained from death certiﬁcates, which were provided by the
Ministry of Health, Labour and Welfare and were used with
permission. Mortality data was classiﬁed according to the Inter-
national Classiﬁcation of Diseases, Tenth Revision. Resident regis-
tration and death registration are required by law in Japan, and the
registries are believed to be complete. We have followed subjects
from the starting point until the end of follow-up in each analysis.
Changes in residence status, including deaths, were identiﬁed
annually through the residential registry in each area. The pro-
portion of subjects lost to follow-up was less than 1%.
We identiﬁed cancer occurrence using active patient notiﬁca-
tion from major local hospitals in the study area and data linkage
with population-based cancer registries. Death certiﬁcate infor-
mation was used as a supplement. Cases were coded using the
International Classiﬁcation of Diseases for Oncology, Third Edition.
In our study, the proportion of case patients with prostate cancer
ascertained by death certiﬁcate only (DCO) was less than 5%.Fig. 1. The association between alcohol drinking, smoking, and prostate cancer according to
ratio.Hazard ratios (HRs) and their 95% conﬁdence intervals (CIs)
were used to describe the relative risk of the incidence of prostate
cancer. The Cox proportional hazards model was used for this
analysis, after controlling for potential confounding factors.
3. Lifestyle risk factors for prostate cancer: smoking and
alcohol consumption
The associations of smoking and alcohol consumption with
prostate cancer are shown in Fig. 1.9 Although alcohol drinking and
smoking have not been established as risk factors for prostate
cancer, they are important risk factors for other types of cancer. The
report by the World Cancer Research Fund International's Contin-
uous Update Project concluded that the data were too limited to
determine an association between alcohol consumption and pros-
tate cancer.10 Regarding smoking, the International Agency for
Research on Cancer does not consider prostate cancer to be related
to tobacco use.11 However, the United States Surgeon General re-
ported that the evidence is suggestive of a higher risk of death from
prostate cancer in smokers than in nonsmokers.12 In addition,
alcohol drinkers and smokers might be less likely to receive
screening, which might mask a positive association. We investi-
gated the association of alcohol drinking and smoking with pros-
tate cancer according to stage, as well as with prostate cancer
detected by subjective symptoms, in a large prospective study of
Japanese men. We evaluated 48,218 men aged 40e69 years who
completed a questionnaire at baseline in 1990e1994 and whowere
followed until the end of 2010. During 16 years of follow-up, 913
menwere newly diagnosed with prostate cancer, of whom 248 had
advanced cases, 635 had localized cases, and 30 were of an unde-
termined stage. To exclude the inﬂuence of screening, we analyzed
the association of prostate cancer with alcohol consumption instage in Japanese men.9 The error bars indicate the 95% conﬁdence interval. HR, hazard
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cases of prostate cancer, of which 103 were advanced cases and 121
were organ-localized). Results showed a positive association of
alcohol consumption with prostate cancer in subjects with
advanced disease: compared to non-drinkers, increased risks were
observed for those who consumed 0e149 g/week (HR 1.82; 95% CI,
0.98e3.38), 150e299 g/week (HR 1.84; 95% CI, 0.99e3.42), and
S300 g/week (HR 1.86; 95% CI, 1.01e3.44) (p for trend ¼ 0.02).
Smoking tended to be associated with an increased risk of
advanced prostate cancer: compared to never smokers, nonsignif-
icantly increased risks were observed for 0e19 pack-years (HR 1.54;
95% CI, 0.70e3.43), 20e39 pack-years (HR 1.43; 95% CI, 0.78e2.60),
and 40 pack-years (HR 1.31; 95% CI, 0.68e2.53) (p for
trend ¼ 0.16). In conclusion, abstinence from alcohol and tobacco
might be important factors in the prevention of advanced prostate
cancer.4. Typical Japanese diet
The World Cancer Research Fund International's Continuous
Update Project reported that the evidence of an association ofFig. 2. The association between isoﬂavones, soy foods, and prostate cancer according to sta
ratio; Q, quartile.prostate cancer with higher consumption of dairy products, diets
high in calcium, low plasma alpha-tocopherol concentration, and
low plasma selenium concentration is limited,10 and there are not
many epidemiological studies on prostate cancer in Asia. To
investigate the association of the Japanese traditional diet with
prostate cancer in the Japanese population is informative, given the
low incidence of prostate cancer comparedwithWestern countries.5. Isoﬂavones and soy foods
The associations of the consumption of isoﬂavones and soy
foods with prostate cancer are shown in Fig. 2.13,14 The World
Cancer Research Fund International's Continuous Update Project
concluded that limited data were suggestive of an association be-
tween soy food intake and prostate cancer.10 Although isoﬂavones
have been suggested to have a preventive effect against prostate
cancer in animal experiments, the results of epidemiological
studies have been inconsistent. We conducted a population-based
prospective study in 43,509 Japanese men aged 45e74 years who
responded to a validated food frequency questionnaire. During
follow-up from 1995 through 2004, 307 men were newlyge in Japanese men.13 The error bars indicate the 95% conﬁdence interval. HR, hazard
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218 were localized cases, and 15 were of an undetermined stage.
Intakes of genistein, daidzein, miso soup, and soy food decreased
the risk of localized prostate cancer. These results were strength-
ened when analysis was conﬁned to men aged >60 years; higher
intake of isoﬂavones and soy food were inversely associated with
the risk of localized cancer in a dose-dependent manner, with HRs
for men in the highest compared with the lowest quartile of gen-
istein, daidzein, and soy food consumption of 0.52 (95% CI,
0.30e0.90), 0.50 (95% CI, 0.28e0.88), and 0.52 (95% CI, 0.29e0.90),
respectively. In contrast, positive associations were seen between
intake of isoﬂavones and incidence of advanced prostate cancer. In
conclusion, we found that isoﬂavone intake was associated with a
decreased risk of localized prostate cancer.
We also conducted a nested case-control study within the JPHC
Study to evaluate the bioavailability of isoﬂavones and the effects of
equol, a metabolite of daidzein produced by intestinal bacteria that
is known to have stronger estrogenic activity than daidzein. A totalFig. 3. The association between green tea intake and prostate cancer according to stage in
Table 1
Summary of the association between lifestyle, diet, and prostate cancer in the JPHC Stud




Body fatness 16 N
Soy 13 Y
Green tea 15 N
Dairy food 17 [
Saturated fatty acid 17 [
Calcium 17 [
Fruits and Vegetables 18 N
Fiber 19 N
Isoﬂavone in plasma 14 Y
Testosterone in plasma 20 N
Sex hormone binding globulin in plasma 20 [
Organochlorines in plasma 21 N
JPHC, Japan Public Health Center; NA, no association.
a The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon
b World Cancer Research Fund/American Institute for Cancer Research. Continuous Upd
Cancer. [Internet,http://www.wcrf.org/int/research-we-fund/continuous-update-project-of 14,203 men aged 40e69 years who had returned the baseline
questionnaire and provided blood samples were followed from
1990 to 2005. During a mean 12.8 years of follow-up, 201 newly
diagnosed prostate cancers were identiﬁed. Two matched controls
for each case were selected from the cohort. Conditional logistic
regressionmodeling was used to estimate the odds ratios (ORs) and
95% CIs for prostate cancer in relation to plasma levels of isoﬂavone.
Although plasma daidzein showed no association, the highest ter-
tile for plasma equol was signiﬁcantly associated with a decreased
risk of localized cancer, with ORs in the highest group of plasma
genistein and equol compared with the lowest group of 0.54 (95%
CI, 0.29e1.01; Ptrend ¼ 0.03) and 0.43 (95% CI, 0.22e0.82;
Ptrend ¼ 0.02), respectively. Plasma isoﬂavone levels were not
signiﬁcantly associated with the risk of advanced prostate cancer.
The results of this study were consistent with the results of our
study about the inverse association between localized prostate
cancer and soy and isoﬂavone intake.Japanese men.15 The error bars indicate the 95% conﬁdence interval. HR, hazard ratio.
y.
esults from JPHC study International evaluation
ocalized Advanced
A [suggestive [suggestive (death)a
A [ Limited-no conclusionb
A NA [Probable (advanced)b
[suggestive Limited-no conclusionb
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ate Project Report. Food, Nutrition, Physical Activity, and the Prevention of Prostate
ﬁndings-reports/prostate-cancer]. AICR. 2011 [cited 2016 April 1].
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The association of green tea intake with prostate cancer is
shown in Fig. 3.15
The World Cancer Research Fund International's Continuous
Update Project concluded that data were insufﬁcient to draw a
conclusion for the association between green tea intake and pros-
tate cancer.10 In general, green tea has a high content of catechins,
which play an important role in cancer prevention. Given the high
consumption of green tea in Asia, it has been suggested that the low
incidence of prostate cancer among Asians may be partly due to the
effects of green tea. We conducted a cohort analysis of the possible
association between green tea and prostate cancer risk among
49,920 men aged 40e69 years who completed a questionnaire and
were followed from 1990 to 2004. During this time, 404 men were
newly diagnosed with prostate cancer, of whom 114 had advanced
cases, 271 had localized cases, and 19 were of an undetermined
stage. Green tea was not associated with localized prostate cancer.
However, green tea consumption was associated with a dose-
dependent decrease in the risk of advanced prostate cancer. The
HR was 0.52 (95% CI, 0.28e0.96) for men drinking 5 cups/day
compared with those consuming <1 cup/day (Ptrend ¼ 0.01). Green
tea may be associated with a decreased risk of advanced prostate
cancer.
7. Conclusion
We elucidated the association of various lifestyle factors with
prostate cancer according to stage in Japanese men (Table 1).16e21
However, epidemiological study of prostate cancer is insufﬁcient,
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